• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.带状疱疹疫苗接种者中 50-59 岁人群的水痘-带状疱疹病毒特异性抗体应答。
J Infect Dis. 2013 Nov 1;208(9):1386-90. doi: 10.1093/infdis/jit342. Epub 2013 Aug 1.
2
Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.带状疱疹疫苗与四价流感病毒疫苗联合接种的免疫原性和安全性。
Vaccine. 2018 Jan 2;36(1):179-185. doi: 10.1016/j.vaccine.2017.08.029. Epub 2017 Aug 19.
3
Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.带状疱疹疫苗在接受慢性/维持性皮质类固醇治疗的受试者中的安全性、耐受性和免疫原性。
Vaccine. 2015 Jun 17;33(27):3129-34. doi: 10.1016/j.vaccine.2015.04.090. Epub 2015 May 8.
4
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.带状疱疹疫苗在带状疱疹病史患者中的安全性、耐受性和免疫原性。
Vaccine. 2010 Jun 7;28(25):4204-9. doi: 10.1016/j.vaccine.2010.04.003. Epub 2010 Apr 21.
5
Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.通过基于糖蛋白的酶联免疫吸附测定法测得的抗体滴度的倍增是带状疱疹疫苗保护效果的良好指标，这在疫苗效力曲线中得到了证实。
J Infect Dis. 2014 Nov 15;210(10):1573-81. doi: 10.1093/infdis/jiu279. Epub 2014 May 13.
6
Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.老年人首剂接种带状疱疹疫苗10年后接种第二剂疫苗后的细胞和体液反应
J Infect Dis. 2016 Jan 1;213(1):14-22. doi: 10.1093/infdis/jiv480. Epub 2015 Oct 9.
7
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.带状疱疹疫苗老年接种者中的水痘-带状疱疹病毒特异性免疫反应。
J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.
8
Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.一种带状疱疹疫苗在水痘-带状疱疹病毒血清阴性和低血清阳性健康成年人中的安全性和免疫原性。
Vaccine. 2007 Mar 1;25(11):2139-44. doi: 10.1016/j.vaccine.2006.11.011. Epub 2006 Nov 27.
9
Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.带状疱疹疫苗活病毒在接受抗病毒治疗且病毒学抑制的 CD4+ 细胞计数>200 个/毫升的 HIV 感染成人中的安全性和免疫原性。
Clin Infect Dis. 2018 Nov 13;67(11):1712-1719. doi: 10.1093/cid/ciy242.
10
Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.减毒活带状疱疹疫苗（ZOSTAVAX™）在韩国成年人中的免疫原性和安全性
J Korean Med Sci. 2016 Jan;31(1):13-7. doi: 10.3346/jkms.2016.31.1.13. Epub 2015 Dec 24.

引用本文的文献

1
Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial.重组gE-Fc融合蛋白亚单位疫苗用于≥50岁成人带状疱疹的免疫原性和安全性：一项随机、活性对照、非劣效性试验
Nat Commun. 2025 Aug 15;16(1):7590. doi: 10.1038/s41467-025-62800-z.
2
A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment.一种复制缺陷型γ疱疹病毒疫苗可保护小鼠免受裂解性疾病侵害，并减少潜伏感染的建立。
NPJ Vaccines. 2024 Jun 24;9(1):116. doi: 10.1038/s41541-024-00908-x.
3
Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer.灭活水痘带状疱疹疫苗在自体造血干细胞移植受者以及实体瘤或血液系统癌症患者中的免疫原性。
Open Forum Infect Dis. 2020 Jun 2;7(7):ofaa172. doi: 10.1093/ofid/ofaa172. eCollection 2020 Jul.
4
Vaccination for quality of life: herpes-zoster vaccines.接种疫苗以提高生活质量：带状疱疹疫苗。
Aging Clin Exp Res. 2021 Apr;33(4):1113-1122. doi: 10.1007/s40520-019-01374-5. Epub 2019 Oct 23.
5
Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons.HIV感染者水痘-带状疱疹病毒抗体定量水平与带状疱疹再激活之间的关联。
AIDS Res Ther. 2018 Dec 11;15(1):25. doi: 10.1186/s12981-018-0212-0.
6
High Constitutive Interleukin 10 Level Interferes With the Immune Response to Varicella-Zoster Virus in Elderly Recipients of Live Attenuated Zoster Vaccine.高含量的白细胞介素 10 水平会干扰带状疱疹活疫苗接种老年受种者对水痘带状疱疹病毒的免疫应答。
J Infect Dis. 2019 Apr 8;219(8):1338-1346. doi: 10.1093/infdis/jiy660.
7
Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis.带状疱疹疫苗在 50 岁及以上成人中的疗效、效果和安全性：系统评价和网络荟萃分析。
BMJ. 2018 Oct 25;363:k4029. doi: 10.1136/bmj.k4029.
8
Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.接受 JAK 抑制剂治疗溃疡性结肠炎患者的带状疱疹：机制、流行病学、管理和预防。
Inflamm Bowel Dis. 2018 Sep 15;24(10):2173-2182. doi: 10.1093/ibd/izy150.
9
Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.水痘带状疱疹病毒糖蛋白特异性抗体的广度和功能在人类接种 Zostavax 后得到鉴定。
J Virol. 2018 Jun 29;92(14). doi: 10.1128/JVI.00269-18. Print 2018 Jul 15.
10
Low Rates of Vaccination for Herpes Zoster in Older People Living With HIV.感染艾滋病毒的老年人带状疱疹疫苗接种率低。
AIDS Res Hum Retroviruses. 2018 Jul;34(7):603-606. doi: 10.1089/AID.2017.0315. Epub 2018 May 21.

本文引用的文献

1
A community-based survey of varicella-zoster virus-specific immune responses in the elderly.老年人水痘带状疱疹病毒特异性免疫应答的社区为基础调查。
J Clin Virol. 2012 Sep;55(1):46-50. doi: 10.1016/j.jcv.2012.06.008. Epub 2012 Jul 6.
2
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.带状疱疹疫苗在 50-59 岁人群中的疗效、安全性和耐受性。
Clin Infect Dis. 2012 Apr;54(7):922-8. doi: 10.1093/cid/cir970. Epub 2012 Jan 30.
3
Zoster vaccine: current status and future prospects.带状疱疹疫苗：现状与未来前景。
Clin Infect Dis. 2010 Jul 15;51(2):197-213. doi: 10.1086/653605.
4
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.年龄和原发感染性质对水痘-带状疱疹病毒特异性细胞免疫应答的影响。
J Infect Dis. 2010 Apr 1;201(7):1024-30. doi: 10.1086/651199.
5
Immune response to a refrigerator-stable zoster vaccine.对一种可在冰箱保存的带状疱疹疫苗的免疫反应。
Clin Vaccine Immunol. 2009 Sep;16(9):1381; author reply 1381-2. doi: 10.1128/CVI.00338-08.
6
A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses.一种用于在临床标本中鉴定和区分水痘-带状疱疹病毒和单纯疱疹病毒野生型及疫苗株的实时聚合酶链反应检测方法，并与临床诊断结果进行比较。
J Med Virol. 2009 Jul;81(7):1310-22. doi: 10.1002/jmv.21506.
7
Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay.水痘带状疱疹病毒（VZV）特异性细胞介导免疫的检测：VZV皮肤试验与干扰素-γ酶联免疫斑点试验的比较
J Infect Dis. 2008 Nov 1;198(9):1327-33. doi: 10.1086/592219.
8
Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).带状疱疹的预防：免疫实践咨询委员会（ACIP）的建议。
MMWR Recomm Rep. 2008 Jun 6;57(RR-5):1-30; quiz CE2-4.
9
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.带状疱疹疫苗老年接种者中的水痘-带状疱疹病毒特异性免疫反应。
J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.
10
The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.用于定量检测水痘带状疱疹病毒（VZV）抗体的糖蛋白酶联免疫吸附测定（ELISA）的优化与验证
J Med Virol. 2006 Dec;78(12):1679-87. doi: 10.1002/jmv.20754.

带状疱疹疫苗接种者中 50-59 岁人群的水痘-带状疱疹病毒特异性抗体应答。

Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.

机构信息

University of Colorado Denver Anschutz Medical Campus, Aurora.

出版信息

J Infect Dis. 2013 Nov 1;208(9):1386-90. doi: 10.1093/infdis/jit342. Epub 2013 Aug 1.

DOI:10.1093/infdis/jit342
PMID:23908486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4550114/
Abstract

Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.

摘要

在带状疱疹疫苗（ZV）疗效试验（N=22439）的免疫原性子研究中，对 50-59 岁受试者的预接种和 6 周后接种样本（n=2269）进行了水痘带状疱疹病毒特异性抗体反应检测。与安慰剂组相比，ZV 组的水痘带状疱疹病毒几何平均滴度（GMT）和几何平均倍数升高更高（GMT，660.0 对 293.1 糖蛋白酶联免疫吸附试验单位/ml[P<0.001]；几何平均倍数升高，2.31 对 1.00[P<0.025]）。在每组中，接种后 GMT 与随后发生带状疱疹的风险之间存在很强的负相关关系。尽管这些数据提供了与 ZV 诱导的抗体和带状疱疹风险相关的强有力证据，但未确定保护阈值。临床试验注册。NCT00534248。